Hyperarousal in insomnia and hypnotic dose escalation.
Given concerns about the abuse liability of hypnotics, this study assessed hyperarousal in people with insomnia and its relation to hypnotic self-administration over 12 months of nightly hypnotic use.



Ninety-five subjects with insomnia (age 32-64 years) underwent screening nocturnal polysomnogram (NPSG) and Multiple Sleep Latency Test (MSLT) the following day and, then, were randomized to receive zolpidem 10 mg or placebo nightly for 12 months. NPSGs and MSLTs were conducted and urine was collected (0700-1500 h) and analyzed for norepinephrine (NE) levels during months one and eight on study medication. A subset (n = 54) underwent hypnotic self-administration assessments in months one, four, and 12.



Mean daily sleep latency on screening MSLT was distributed across the full range of MSLT latencies (2-20 min). The highest screening MSLT latencies were detected in subjects with higher NE levels, compared to those with the lowest MSLT latencies. In the subset undergoing self-administration assessment, those with the highest MSLT latencies chose more capsules (placebo and zolpidem) and increased the number of capsules chosen in months four relative to month one, compared to those with the lowest MSLT latencies.



These data show that some insomniacs are hyperaroused with high MSLT/NE levels and, compared to low MSLT/NE insomniacs, they increase the number of capsules (zolpidem and placebo) self-administered on months four and 12 relative to Month one.
Sleep Disorders and Research Center, Henry Ford Hospital, Detroit, MI, USA; Psychiatry and Behavioral Neurosciences, Wayne State University, Detroit, MI, USA. Electronic address: troehrs1@hfhs.org.
T A
TA
Roehrs
Sleep Disorders and Research Center, Henry Ford Hospital, Detroit, MI, USA; Psychiatry and Behavioral Neurosciences, Wayne State University, Detroit, MI, USA.
T
T
Roth
D000328:Adult; D000368:Aged; D001143:Arousal; D005260:Female; D006801:Humans; D006993:Hypnotics and Sedatives / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009638:Norepinephrine / Q000652:urine; D017286:Polysomnography; D011725:Pyridines / Q000008:administration & dosage / Q000627:therapeutic use*; D020921:Sleep Arousal Disorders / Q000188:drug therapy* / Q000503:physiopathology / Q000652:urine; D007319:Sleep Initiation and Maintenance Disorders / Q000188:drug therapy* / Q000503:physiopathology / Q000652:urine; D000074361:Sleep Latency / Q000502:physiology; D055815:Young Adult; D000077334:Zolpidem
D006993:Hypnotics and Sedatives; D011725:Pyridines; D000077334:Zolpidem; D009638:Norepinephrine
Hypnotic self-administration; Insomnia; MSLT; NE
Sleep. 2001 Feb 1;24(1):110-7
11204046
Sleep. 2000 Jun 15;23(4):504-10
10875557
Sleep. 1986 Dec;9(4):519-24
3809866
Sleep. 2012 Nov 01;35(11):1551-7
23115404
Am J Psychiatry. 2004 Nov;161(11):2126-8
15514418
Sleep. 1984;7(3):230-8
6484427
Sleep. 1995 Sep;18(7):581-8
8552929
Sleep. 2011 Dec 01;34(12):1647-52
22131601
J Clin Endocrinol Metab. 2001 Aug;86(8):3787-94
11502812
Ann N Y Acad Sci. 2008 Oct;1141:105-30
18991954
Sleep. 1997 Dec;20(12):1127-34
9493922
Psychosom Med. 1998 Sep-Oct;60(5):610-5
9773766
Sleep. 1994 Dec;17(8):693-702
7701180
J Clin Psychiatry. 2005;66 Suppl 9:31-41
16336040
Curr Top Behav Neurosci. 2014;21:277-90
24920447
J Psychopharmacol. 2012 Aug;26(8):1088-95
22004689